Syndax Pharmaceuticals (NASDAQ:SNDX) Getting Somewhat Favorable Press Coverage, Analysis Finds

Media stories about Syndax Pharmaceuticals (NASDAQ:SNDX) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a news impact score of 0.20 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 48.1419127306708 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

SNDX stock traded down $1.29 during midday trading on Thursday, reaching $13.34. 266,443 shares of the company were exchanged, compared to its average volume of 410,765. Syndax Pharmaceuticals has a one year low of $7.41 and a one year high of $15.43. The stock has a market cap of $360.59, a price-to-earnings ratio of -4.60 and a beta of 1.13.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, March 5th. The company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.76) by ($0.04). Syndax Pharmaceuticals had a negative return on equity of 63.51% and a negative net margin of 2,884.34%. The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $0.75 million. The firm’s revenue for the quarter was up 290.2% compared to the same quarter last year. research analysts expect that Syndax Pharmaceuticals will post -3.52 EPS for the current fiscal year.

A number of research firms have recently issued reports on SNDX. B. Riley reiterated a “buy” rating and issued a $40.00 price objective on shares of Syndax Pharmaceuticals in a report on Thursday, January 18th. BidaskClub upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd. Zacks Investment Research upgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Wednesday, January 10th. Morgan Stanley lowered their target price on shares of Syndax Pharmaceuticals from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Wednesday, March 14th. Finally, ValuEngine upgraded shares of Syndax Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, March 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $23.86.

In other news, insider Peter Ordentlich sold 7,500 shares of the business’s stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $15.00, for a total value of $112,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 24.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Syndax Pharmaceuticals (NASDAQ:SNDX) Getting Somewhat Favorable Press Coverage, Analysis Finds” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://baseballnewssource.com/2018/04/06/syndax-pharmaceuticals-sndx-receives-daily-news-sentiment-rating-of-0-20/2029273.html.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Insider Buying and Selling by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.